Showing 4471-4480 of 5771 results for "".
- Nova Eye Medical Establishes “AlphaRET” to Fulfill the Commercial Development of 2RThttps://modernod.com/news/nova-eye-medical-establishes-alpharet-to-fulfill-the-commercial-development-of-2rt/2478458/Nova Eye Medical has announced the reorganization of its 2RT assets via the establishment of AlphaRET Pty Ltd. Establishing AlphaRET, a wholly owned subsidiary of Nova Eye Medical Limited, will enable the company to better concentrate its commercialization efforts for 2RT, and delineate th
- FDA Approves Vanda Pharmaceuticals’ IND Application for VSJ-110 for Allergic Conjunctivitishttps://modernod.com/news/fda-approves-vanda-pharmaceuticals-ind-application-for-vsj-110-for-allergic-conjunctivitis/2478459/Vanda Pharmaceuticals announced that the FDA has approved the investigational new drug (IND) application to evaluate Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activator VSJ-110 (previously known as CFTRact-K267) for the treatment of allergic conjunctivitis. R
- AstraZeneca, J&J Say Their COVID-19 Vaccine Trials Back on Track in UShttps://modernod.com/news/astrazeneca-jj-say-their-covid-19-vaccine-trials-back-on-track-in-us/2478455/AstraZeneca announced Friday that it has been cleared to restart its phase 3 COVID-19 vaccine trial in the US. The company, which is co-developing AZD1222 with the University of Oxford, had paused global testing of the vaccine candidate early last month after a UK participant fell ill with what i
- Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Mont Blanc Phase 3 Trialhttps://modernod.com/news/nicoxs-ncx-470-receives-approval-by-chinese-authorities-for-local-start-of-mont-blanc-phase-3-trial/2478456/Nicox SA announced that its partner, Ocumension Therapeutics, has received approval from China’s Center for Drug Evaluation of the National Medical Products Administration to carry out the Chinese part of the ongoing Mont Blanc trial, the first phase 3 clinical trial on NCX 470 for the lowering o
- FDA Accepts Santen’s NDA for Cyclosporine Topical Ophthalmic Emulsion for the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18https://modernod.com/news/fda-accepts-santens-nda-for-cyclosporine-topical-ophthalmic-emulsion-for-the-treatment-of-severe-vernal-keratoconjunctivitis-in-patients-ages-4-18/2478457/Santen announced that the FDA has accepted the new drug application (NDA) for cyclosporine topical ophthalmic emulsion 0.1% for the treatment of severe vernal keratoconjunctivitis (VKC) in patients ages 4-18. The FDA has set June 26, 2021 as the Prescription Drug Use
- Visus Therapeutics Expands Clinical Advisory Board With Appointment of Renowned Ophthalmologistshttps://modernod.com/news/visus-therapeutics-expands-clinical-advisory-board-with-appointment-of-renowned-ophthalmologists/2478453/Visus Therapeutics announced the appointments of prominent ophthalmologists Marguerite McDonald, MD, Neda Shamie, MD, William Trattler, MD, and Lawrence Woodard, MD, to its clinical advisory board. Drs. McDonald, Shamie, Trattler and Woodard will lend their decades of experience in clinical pract
- Moderna Hits 30,000 Enrollment Target in Phase 3 Coronavirus Vaccine Trialhttps://modernod.com/news/moderna-hits-30000-enrollment-target-in-phase-3-coronavirus-vaccine-trial/2478450/Moderna announced that it has completed enrollment of 30,000 participants in the phase 3 COVE study of its investigational coronavirus vaccine mRNA-1273. More than 25,650 participants have so far received their second dose, and Moderna said it will decide whether to seek emergency-use autho
- Nicox Selects Development Candidate in a New Class of NO-Mediated IOP Lowering Agentshttps://modernod.com/news/nicox-selects-development-candidate-in-a-new-class-of-no-mediated-iop-lowering-agents/2478452/Nicox SA announced that it has selected a new development candidate, NCX 1728, from its proprietary research program focused on nitric oxide (NO)-mediated IOP lowering agents. An analog of this molecule has demonstrated positive results in ocular hypertensive
- Rayner Launches Raytrace Premium IOL Calculator Update to Include Posterior Corneal Astigmatismhttps://modernod.com/news/rayner-launches-raytrace-premium-iol-calculator-update-to-include-posterior-corneal-astigmatism/2478444/Rayner announced the launch of their updated web-based premium IOL calculator, Raytrace. Developed in line with surgeon feedback, the new Raytrace version 3.5 includes the following improvements: Inclusion of Posterior Corneal Astigmatism (PCA) for more accurate toric IOL calculation
- Azura Ophthalmics Raises $20 Million for Registration Studies for Treatment of Meibomian Gland Dysfunctionhttps://modernod.com/news/azura-ophthalmics-raises-20-million-for-registration-studies-for-treatment-of-meibomian-gland-dysfunction/2478445/Azura Ophthalmics announced a $20 million financing to advance Azura’s lead product candidate AZR-MD-001 through a registration study for the treatment of meibomian gland dysfunction (MGD). Azura’s novel medicines in development are designed to address abnormal hyperkeratinization – the bu